Matinas BioPharma Holdings Inc (NASDAQ:MTNB) has been assigned a $6.00 price objective by equities research analysts at Maxim Group in a report issued on Tuesday. The brokerage presently has a “buy” rating on the stock. Maxim Group’s target price suggests a potential upside of 319.58% from the company’s current price.

Separately, Roth Capital initiated coverage on shares of Matinas BioPharma Holdings in a research report on Monday, July 10th. They issued a “buy” rating and a $9.00 target price for the company.

Matinas BioPharma Holdings (MTNB) traded up 14.40% during trading on Tuesday, hitting $1.43. 640,549 shares of the stock were exchanged. The stock’s market capitalization is $130.70 million. Matinas BioPharma Holdings has a 52 week low of $0.63 and a 52 week high of $3.99. The firm has a 50-day moving average of $1.66 and a 200-day moving average of $2.56.

Matinas BioPharma Holdings (NASDAQ:MTNB) last announced its earnings results on Tuesday, May 16th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.04) by $0.21. The business had revenue of $0.02 million during the quarter. Matinas BioPharma Holdings had a negative net margin of 30,034.20% and a negative return on equity of 1,227.85%. Equities research analysts anticipate that Matinas BioPharma Holdings will post ($0.26) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Matinas BioPharma Holdings Inc (MTNB) PT Set at $6.00 by Maxim Group” was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another site, it was stolen and reposted in violation of US & international copyright law. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/08/matinas-biopharma-holdings-nasdaqmtnb-buy-rating-reaffirmed-at-maxim-group.html.

A number of large investors have recently bought and sold shares of the company. Spark Investment Management LLC purchased a new stake in Matinas BioPharma Holdings during the first quarter valued at $105,000. Alps Advisors Inc. purchased a new stake in Matinas BioPharma Holdings during the second quarter valued at $139,000. Schwab Charles Investment Management Inc. purchased a new stake in Matinas BioPharma Holdings during the second quarter valued at $152,000. Segantii Capital Management Ltd purchased a new stake in Matinas BioPharma Holdings during the first quarter valued at $166,000. Finally, KCG Holdings Inc. purchased a new stake in Matinas BioPharma Holdings during the first quarter valued at $193,000.

About Matinas BioPharma Holdings

Matinas BioPharma Holdings, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections.

Receive News & Ratings for Matinas BioPharma Holdings Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas BioPharma Holdings Inc and related companies with MarketBeat.com's FREE daily email newsletter.